Live Feeds
● LIVE Updated 1h ago · 14 sources tracked

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

The US Food and Drug Administration declined to approve Summit Therapeutics' lung cancer drug ivonescimab after a clinical trial missed a key survival goal. The rejection derails the United States arrival of the much-hyped PD-1xVEGF class of treatments and serves as a blow to Beijing's biotech sector, as the drug was invented in China by partner Akeso. Following the regulatory decision, Summit Therapeutics provided an update regarding the biologics license application while company stock plunged overnight.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (14)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The US Food and Drug Administration declined to approve Summit Therapeutics' lung cancer drug ivonescimab.
  • ✓ The rejection occurred after a trial missed a key survival goal.
  • ✓ Ivonescimab was invented in China by partner Akeso.
🛡️ Source Corroboration: 14 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The US Food and Drug Administration officially declined to approve the lung cancer drug ivonescimab after its trial missed a key survival goal.

Live updates

  1. FDA Declines to Approve Summit Lung Cancer Drug Ivonescimab

    The US Food and Drug Administration declined to approve Summit Therapeutics' lung cancer drug ivonescimab after a clinical trial missed a key survival goal. The rejection derails the United States arrival of the much-hyped PD-1xVEGF class of treatments and serves as a blow to Beijing's biotech sector, as the drug was invented in China by partner Akeso. Following the regulatory decision, Summit Therapeutics provided an update regarding the biologics license application while company stock plunged overnight.

    Why it matters

    The decision halts the introduction of a closely watched therapy that originated in China, impacting broader industry expectations for cross-border drug development. Ivonescimab targets a narrow lung cancer setting, creating high stakes for both Summit and its Chinese partner Akeso. Regulatory scrutiny on survival goals remains a strict hurdle for foreign-developed immunotherapies seeking US market entry.

    What is confirmed

    • The US Food and Drug Administration declined to approve Summit Therapeutics' lung cancer drug ivonescimab.
    • The rejection occurred after a trial missed a key survival goal.
    • Ivonescimab was invented in China by partner Akeso.

    What to watch next

    • Further statements from Summit Therapeutics regarding regulatory next steps for ivonescimab
    • Potential protocol adjustments or new trial designs to address the missed survival goal
    Sources used for this update (13)
    1. consent.yahoo.com — Latest news and current events updates | Yahoo News Singapore
    2. www.marketscreener.com — Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
    3. digg.com — Microsoft, Alphabet and 14 others object to OKXICE’s tokenized-stock plans · Digg
    4. arynews.tv — Iran says four tankers on fire after hitting mines in Hormuz
    5. Fierce Pharma — FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
    6. Reuters — US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
    7. Yahoo Finance — Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
    8. Bloomberg.com — US FDA Rejects Summit’s China-Originated Lung Cancer Drug
    9. Endpoints News — FDA rejects Summit, Akeso’s ivonescimab in narrow lung cancer setting
    10. Financial Times — FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
    11. The New York Times — F.D.A. Rejects Closely Watched Lung Cancer Drug From China
    12. Yahoo Finance — SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community